The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes

M. P. Barrett; A. H. Fairlamb

doi:10.1016/S0169-4758(99)01414-3

The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes

M. P. Barrett (Lead / Corresponding author), A. H. Fairlamb

Research output: Contribution to journal › Review article › peer-review

132 Citations (Scopus)

Abstract

Resistance to currently used drugs is a serious problem in most fields of antimicrobial chemotherapy. Crossresistance between two of the major classes of drug used in the treatment of African trypanosomiasis, the melaminophenyl arsenicals and diamidines is easily selected in the laboratory. Here, Mike Barrett and Alan Fairlamb outline the mechanism underlying this crossresistance, which appears to arise as a result of alterations in an unusual adenosine transporter involved in the uptake of these drugs.

Original language	English
Pages (from-to)	136-140
Number of pages	5
Journal	Parasitology Today
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/S0169-4758(99)01414-3
Publication status	Published - 1 Apr 1999

ASJC Scopus subject areas

Parasitology

Access to Document

10.1016/S0169-4758(99)01414-3

Cite this

@article{60c0bb0a2bcd422a8cd587029c5b77b9,

title = "The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes",

abstract = "Resistance to currently used drugs is a serious problem in most fields of antimicrobial chemotherapy. Crossresistance between two of the major classes of drug used in the treatment of African trypanosomiasis, the melaminophenyl arsenicals and diamidines is easily selected in the laboratory. Here, Mike Barrett and Alan Fairlamb outline the mechanism underlying this crossresistance, which appears to arise as a result of alterations in an unusual adenosine transporter involved in the uptake of these drugs.",

author = "Barrett, {M. P.} and Fairlamb, {A. H.}",

note = "Funding Information: MPB and AHF are grateful to the Wellcome Trust for financial support.",

year = "1999",

month = apr,

day = "1",

doi = "10.1016/S0169-4758(99)01414-3",

language = "English",

volume = "15",

pages = "136--140",

journal = "Parasitology Today",

issn = "0169-4758",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes

AU - Barrett, M. P.

AU - Fairlamb, A. H.

N1 - Funding Information: MPB and AHF are grateful to the Wellcome Trust for financial support.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - Resistance to currently used drugs is a serious problem in most fields of antimicrobial chemotherapy. Crossresistance between two of the major classes of drug used in the treatment of African trypanosomiasis, the melaminophenyl arsenicals and diamidines is easily selected in the laboratory. Here, Mike Barrett and Alan Fairlamb outline the mechanism underlying this crossresistance, which appears to arise as a result of alterations in an unusual adenosine transporter involved in the uptake of these drugs.

AB - Resistance to currently used drugs is a serious problem in most fields of antimicrobial chemotherapy. Crossresistance between two of the major classes of drug used in the treatment of African trypanosomiasis, the melaminophenyl arsenicals and diamidines is easily selected in the laboratory. Here, Mike Barrett and Alan Fairlamb outline the mechanism underlying this crossresistance, which appears to arise as a result of alterations in an unusual adenosine transporter involved in the uptake of these drugs.

UR - http://www.scopus.com/inward/record.url?scp=0033119815&partnerID=8YFLogxK

U2 - 10.1016/S0169-4758(99)01414-3

DO - 10.1016/S0169-4758(99)01414-3

M3 - Review article

C2 - 10322334

AN - SCOPUS:0033119815

SN - 0169-4758

VL - 15

SP - 136

EP - 140

JO - Parasitology Today

JF - Parasitology Today

IS - 4

ER -

The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this